CollPlant Biotechnologies Ltd (CLGN) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18
	20-F	20-F	20-F	20-F
Revenues:
Europe	0.6	0.4	0.2
United states and Canada	15.0	5.8	2.1
Total revenues	15.6	6.1	2.3	5.0
Revenue growth [+]	154.9%	164.8%	-53.8%
Europe	70.2%	53.8%
United states and Canada	160.3%	177.6%
Cost of goods sold	2.0	3.0	1.9	1.7
Gross profit	13.6	3.1	0.4	3.4
Gross margin	87.2%	51.1%	18.9%	66.9%
Selling, general and administrative [+]	5.9	4.7	3.7	3.7
General and administrative	5.9	4.7	3.7	3.7
Research and development	7.6	4.1	4.4	3.9
Other operating expenses				-8.5
EBITDA [+]	0.8	-4.9	-7.1	4.6
EBITDA growth	-117.0%	-30.4%	-254.6%
EBITDA margin	5.4%	-80.5%	-306.0%	91.5%
Depreciation and amortization	0.8	0.7	0.5	0.3
EBIT [+]	0.1	-5.6	-7.6	4.2
EBIT growth	-101.2%	-26.6%	-279.8%
EBIT margin	0.4%	-91.2%	-329.2%	84.7%
Interest income	-0.2	0.2	3.5
Interest income	-0.2	0.2	3.5
Other income (expense), net	0.3	-0.4	-7.1	-10.5
Pre-tax income	0.2	-5.8	-11.2	-6.2
Income taxes	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%
Net income	0.2	-5.8	-11.2	-6.2
Net margin	1.5%	-94.1%	-481.6%	-124.6%

Basic EPS [+]	$0.02	($0.84)	($2.24)	($1.43)
Growth	-102.8%	-62.6%	57.1%
Diluted EPS [+]	$0.02	($0.84)	($2.24)	($1.43)
Growth	-102.4%	-62.6%	57.1%

Shares outstanding (basic) [+]	10.0	6.9	5.0	4.4
Growth	44.8%	38.1%	13.7%
Shares outstanding (diluted) [+]	12.0	6.9	5.0	4.4
Growth	73.8%	38.1%	13.7%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.